**TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED**
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

---

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND APPLICATION FOR CHANGES IN THE INDUSTRIAL AND COMMERCIAL REGISTRATION**

---

***The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.***

The Board refers to the announcement dated 14 August 2026 made by the Company in relation to the resolutions passed at the 7th Board meeting for the financial year ending 31 December 2026 (the "**FY2026 7th Board Meeting Announcement**"), and in particular to the resolution relating to the proposed amendments to the Articles of Association of the Company (the "**2026 Proposed AOA Amendments**") and the application for changes in the industrial and commercial registration.

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the FY2026 7th Board Meeting Announcement.*

Pursuant to the applicable laws, regulations and regulatory documents, including the *Company Law of the People's Republic of China (《中华人民共和国公司法》)* (the "**PRC Company Law**") and the revised *Guidelines for Articles of Association of Listed Companies (《上市公司章程指引》)* promulgated by the China Securities Regulatory Commission (中国证券监督管理委员会) in March 2025, and taking into account the Company's actual management needs, the Company proposes to amend its Articles of Association with a view to further standardising its corporate governance structure.

The proposed amendments to the existing Articles of Association are set out below (with insertions in bold and underline, and deletions in bold strikethrough):

| Before the 2026 Proposed AOA Amendments | After the 2026 Proposed AOA Amendments |
|---|---|
| **Article 4** The legal representative of the Company is the Chairman of the Board of Directors. | **Article 4** <u>**The General Manager shall be the legal representative of the Company.**</u> **~~The legal representative of the Company is the Chairman of the Board of Directors.~~**<br><br><u>**If the General Manager resigns from office, he or she shall be deemed to have resigned as the legal representative of the Company simultaneously.**</u><br><br><u>**If the legal representative resigns from office, the Company shall designate a new legal representative within thirty (30) days from the date of such resignation.**</u> |

Save for the above amendments, all other provisions of the Articles of Association of the Company shall remain unchanged.

The 2026 Proposed AOA Amendments shall be submitted to the shareholders of the Company (the "**Shareholders**") for consideration at a general meeting of the Company to be convened in due course and shall require the approval of Shareholders representing more than two-thirds (2/3) of the voting rights held by the Shareholders attending such meeting, in accordance with the PRC Company Law.

**By order of the Board**

Jiao Yan
Secretary to the Board of Directors
14 August 2026